Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission (SEC) filings for Sera Prognostics, Inc. (NASDAQ: SERA), a Salt Lake City–based health diagnostics company focused on precision pregnancy care and preterm birth risk prediction. As a public company, Sera files annual, quarterly, and current reports that describe its financial condition, operations, and key clinical and commercial developments.
Investors can review annual reports on Form 10-K and quarterly reports on Form 10-Q for detailed discussions of Sera’s business, including its focus on the PreTRM® Test, a blood-based biomarker test for individualized risk prediction of spontaneous preterm birth in asymptomatic singleton pregnancies. These filings typically include information on revenues, operating expenses, research and development activities, and risk factors relevant to the company’s diagnostics business.
Current reports on Form 8-K document material events such as the release of quarterly financial results and significant clinical milestones. Recent 8-K filings reference press releases announcing second and third quarter financial results and the acceptance of the PRIME study for publication in a peer-reviewed journal. These filings help readers track how clinical evidence, such as the PRIME randomized controlled trial, connects to Sera’s commercial and strategic plans.
Users can also monitor Form 4 and other insider transaction filings, when available, to see reported trades by directors, officers, or significant shareholders. Stock Titan’s tools surface new SERA filings as they appear in the SEC’s EDGAR system and provide AI-powered summaries to explain key points, highlight important sections in lengthy documents, and make it easier to understand how disclosures about the PreTRM Test, payer engagement, and financial performance may relate to the company’s overall trajectory.
Benjamin G. Jackson, General Counsel of Sera Prognostics, reported the sale of 6,447 shares of Class A common stock on 08/08/2025 to satisfy tax withholding on vested restricted stock units. The filing states this was a mandatory "sell-to-cover" transaction and not a discretionary sale. The shares were executed as a block trade at a weighted average price of $2.54, with individual trade prices ranging from $2.28 to $2.73.
Following the sale the reporting person beneficially owns 127,751 shares on a direct basis. No derivative securities were reported. The disclosure documents an administrative, tax-related disposition rather than an elective insider sale.
Robert Gardner, Chief Information Officer and director at Sera Prognostics, sold shares to satisfy tax withholding from restricted stock units. The Form 4 reports a non-discretionary "sell to cover" transaction on 08/08/2025 in which 5,962 Class A common shares were sold as a block at prices ranging from $2.28 to $2.73, with a weighted average price of $2.54. After the sale the reporting person beneficially owns 108,577 shares. The filing states the sale was mandated by the issuer to satisfy tax obligations and that detailed per-price breakdowns for the block trade will be provided on request. No derivative securities were reported.
Sera Prognostics insider disclosure: John J. Boniface, the company's Chief Scientific Officer, reported a non-discretionary sale of restricted stock to satisfy tax-withholding obligations. On 08/08/2025 the reporting person sold 7,094 shares that were withheld upon the vesting of RSUs; the issuer required a "sell-to-cover" to satisfy taxes.
The filing reports a weighted-average sale price of $2.54 (block trades ranged from $2.28 to $2.73) and shows the reporting person beneficially owns 160,888 shares following the transaction. No derivative transactions were reported.
Sera Prognostics insider transaction summary: Austin Aerts, identified as an officer (Chief Financial Officer), transferred 5,800 shares of Class A common stock in a "sell-to-cover" transaction to satisfy tax withholding from the vesting of restricted stock units (RSUs). The reported weighted-average price for the shares sold was $2.54, with execution prices reported in a range from $2.28 to $2.73. After the transaction, the Reporting Person beneficially owned 290,848 shares.
The filing states the sale was mandated by the issuer's election to fund tax withholding and was executed as part of a block trade; the Reporting Person did not exercise discretion over the sale. No derivative transactions are reported.
Sera Prognostics filed a Form 144 reporting a proposed sale under Rule 144 of 8,571 shares of Class A common stock that were acquired through restricted stock unit vesting on 08/08/2025, with an aggregate market value reported at $21,773. The filing lists 38,061,868 shares outstanding and indicates the transaction would be executed through Morgan Stanley Smith Barney LLC on NASDAQ. The same individual, Zhenya Lindgardt, sold 9,406 shares on 05/08/2025, 23,042 on 06/09/2025 and 3,344 on 06/10/2025, producing reported gross proceeds of $22,974, $33,042 and $4,964 respectively. The filer certifies they are not aware of any undisclosed material adverse information.
Sera Prognostics insider Paul Kearney filed a Form 144 to sell 6,460 Class A common shares of SERA, representing an aggregate market value of $16,410. The securities were acquired by restricted stock unit vesting on 08/08/2025 and the proposed sale is also dated 08/08/2025. The sale is to be executed through Morgan Stanley Smith Barney. The filing reports 38,061,868 shares outstanding for the issuer, giving context to the size of this sale.
The form also discloses two recent sales by the same person: 7,089 shares on 05/08/2025 (gross proceeds $17,315) and 1,311 shares on 06/10/2025 (gross proceeds $1,946). The notice includes the standard insider representation that no undisclosed material adverse information is known to the seller.
Form 144 filing reports a proposed sale of 6,447 Class A Common shares of Sera Prognostics (SERA) through Morgan Stanley Smith Barney on NASDAQ with an aggregate market value of $16,377. The record lists 38,061,868 shares outstanding. The securities were acquired via restricted stock unit vesting from the issuer on 08/08/2025, with the same date shown as the approximate sale date.
The filing also discloses sales in the past three months by Benjamin Jackson: 7,084 shares sold on 05/08/2025 for $17,303 and 965 shares sold on 06/10/2025 for $1,433. Several standard filer contact fields (CIK/CCC and named account fields) are not populated in the provided content.
Sera Prognostics submitted a Form 144 notice proposing the sale of 5,962 Class A common shares, with an aggregate market value of $15,145. The filing reports 38,061,868 shares outstanding, placing the proposed sale in the context of the company's issued share base.
The shares are scheduled for sale on 08/08/2025 on NASDAQ through Morgan Stanley Smith Barney LLC. The securities were acquired by Restricted Stock Unit vesting from the issuer on 08/08/2025, with payment noted as not applicable.
The filing also discloses prior sales by Robert Harrison: 6,551 shares on 05/08/2025 for $16,001 and 667 shares on 06/10/2025 for $990. The signer represents no knowledge of undisclosed material adverse information.
Sera Prognostics' Form 144 shows a proposed sale of 7,094 Class A Common shares through Morgan Stanley Smith Barney on 08/08/2025. The filing states these shares were acquired by Restricted Stock Unit vesting on 08/08/2025 and lists an aggregate market value of 18,021 with 38,061,868 shares outstanding. The filing also discloses sales in the past three months: 5,132 shares on 05/08/2025 (gross proceeds 12,535) and 1,439 shares on 06/10/2025 (gross proceeds 2,136), totaling 6,571 shares sold for 14,671 gross proceeds. The notice includes the required representation that the seller does not possess undisclosed material adverse information.
Sera Prognostics reported an insider notice to sell 5,800 Class A common shares with an aggregate market value of $14,734, planned on 08/08/2025 on NASDAQ. The shares were acquired the same day through Restricted Stock Unit vesting, and the sale is listed with Morgan Stanley Smith Barney LLC. The proposed sale equals approximately 0.015% of the 38,061,868 outstanding shares. In the prior three months the filer sold 6,374; 5,735; and 945 shares for combined gross proceeds of $25,196. The filer certifies no known material nonpublic information.